Pfizer (NYSE:PFE) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Pfizer (NYSE:PFE) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04, FiscalAI reports. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the firm posted $0.92 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer updated its FY 2026 guidance to 2.800-3.000 EPS.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.24 during midday trading on Tuesday, hitting $26.07. 10,815,908 shares of the company’s stock were exchanged, compared to its average volume of 42,342,914. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $148.21 billion, a PE ratio of 19.13 and a beta of 0.35. Pfizer has a 12 month low of $21.97 and a 12 month high of $28.75. The company’s 50 day moving average price is $27.17 and its 200 day moving average price is $26.11.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 earnings and revenue topped expectations, led by strong Eliquis sales and cancer-treatment growth. This is the primary driver behind the early upside in the stock. Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: FDA approved VEPPANU (vepdegestrant) for ESR1‑mutated advanced breast cancer — a near‑term pipeline win that can support long‑term growth expectations. Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
• Positive Sentiment: Management highlighted growth from recently launched and acquired products (including Metsera acquisition) that are helping offset declines in legacy COVID products — a strategic positive for medium‑term revenue diversification. Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
• Neutral Sentiment: Company formally reaffirmed its FY2026 guidance (EPS $2.80–3.00; revenue $59.5B–62.5B) in its press release — provides some clarity for the year but leaves room for execution risk. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
• Negative Sentiment: Guidance and some management commentary were interpreted as conservative — the FY EPS and revenue ranges sit at or slightly below consensus, which is weighing on sentiment despite the beat. PFE Earnings: Pfizer Stock Rises on Q1 Beat despite Lower 2026 Sales Outlook
• Negative Sentiment: Higher R&D spending reduced profit year‑over‑year and may continue to pressure margins in the near term; investors will watch how R&D investment converts to late‑stage wins. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Mcguire Capital Advisors Inc. bought a new position in shares of Pfizer during the fourth quarter worth approximately $64,000. Compound Planning Inc. boosted its stake in shares of Pfizer by 35.5% in the fourth quarter. Compound Planning Inc. now owns 70,555 shares of the biopharmaceutical company’s stock valued at $1,757,000 after buying an additional 18,483 shares during the period. TMB Capital Partners LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $251,000. Axxcess Wealth Management LLC grew its position in Pfizer by 3.3% during the fourth quarter. Axxcess Wealth Management LLC now owns 210,175 shares of the biopharmaceutical company’s stock worth $5,233,000 after buying an additional 6,661 shares in the last quarter. Finally, Birchwood Financial Partners Inc. bought a new position in Pfizer during the 4th quarter worth $38,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PFE shares. Citigroup lifted their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Morgan Stanley raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Royal Bank Of Canada reiterated an “underperform” rating and issued a $25.00 price objective on shares of Pfizer in a report on Monday, April 20th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research report on Monday, March 2nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.74.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.